metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
	nivolumab plus ipilimumab
	CheckMate 451 (NI ; all population), 2019 Annals of Oncology 30 : ii77–ii80, 2019 NCT02538666	RCT	Extensive stage SCLC (Es-SCLC) - maintenance (M)	nivolumab plus ipilimumab	placebo	patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy	279 / 275	some concern	inconclusive	inconclusive 8 % decrease in deaths (OS) (PE) suggested 28 % decrease in progression or deaths (PFS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus etoposide plus platin
	durvalumab plus tremelimumab plus SoC
	CASPIAN (DT ; all population), 2019 Lancet 2019; 394:1929-1939 Lancet December 04, 2020 ESMO Open 2022 Apr;7(2):100408. NCT03043872	RCT	Extensive stage SCLC (Es-SCLC) - 1st Line (L1)	durvalumab plus tremelimumab and etoposide plus either cisplatin or carboplatin	etoposide plus either cisplatin or carboplatin	adults with untreated extensive-stage small-cell lung cancer (SCLC)	268 / 269	some concern	inconclusive	inconclusive 18 % decrease in deaths (OS) (PE)